Santhera Pharmaceuticals CFO Catherine Isted joined Steve Darling from Proactive to discuss the company’s financial results for the six months ended June 30, 2026, highlighting strong commercial momentum for AGAMREE® and significant progress in expanding patient access across international markets. Santhera reported total revenue of CHF 48.3 million for the first half of 2026, representing a 101% increase from CHF 24.0 million during the same period in 2025. The growth was driven by a combination of higher AGAMREE® product sales and increased royalties and milestone income, including proceeds from a major licensing agreement with Nxera. Product sales increased 48% year over year to CHF 17.2 million, compared with CHF 11.6 million in the first half of 2025. Santhera attributed the increase to continued commercial expansion across markets where AGAMREE® has been launched. The company also reported a substantial increase in royalties and milestone income, which rose to CHF 29.1 million from CHF 6.5 million a year earlier. The increase was primarily driven by a US$30 million, or approximately CHF 24.2 million, upfront cash payment received under Santhera’s licensing agreement with Nxera. Revenue from the supply of products and services to partners declined to CHF 2.1 million from CHF 5.9 million, which Santhera said was expected and primarily reflected Catalyst Pharmaceuticals’ transition to direct sourcing. A key commercial milestone during the first half was the expansion of AGAMREE® across Europe. Pricing and reimbursement agreements secured in Spain and Italy mean the treatment is now commercially available in four of the five major European Union markets, adding to established commercial activity in Germany and the UK. Santhera also strengthened its presence in the Asia-Pacific region through an exclusive licensing agreement with Nxera covering Japan, South Korea, Australia and New Zealand. The agreement is valued at up to US$215 million, plus royalties, and includes a US$30 million cash payment and a US$10 million equity investment in Santhera. The company continued to make progress in additional European markets. Swissmedic approved AGAMREE® in Switzerland in January 2026, while a pricing and reimbursement agreement was reached in Luxembourg in August, making it the first Benelux market to secure reimbursement for the treatment. Santhera’s distributor network has also continued to expand. The company broadened its agreement with Biomedica to include Georgia, Kazakhstan, Belarus, Azerbaijan and Uzbekistan, extending the geographic reach of AGAMREE®. In Serbia, distributor Genesis secured marketing authorization for AGAMREE® in September, providing another pathway for expanding patient access across the region. #proactiveinvwstors #six #sann #AGAMREE #Duchenne #DMD #RareDisease #Biopharma #Pharma #Healthcare #LifeSciences #DrugDevelopment #ClinicalData #Europe #APAC #Japan #SouthKorea #Australia #NewZealand #Biotechnology